Current Topics in Medicinal Chemistry

Allen B. Reitz
Fox Chase Chemical Diversity Center, Inc.
Doylestown, PA


Strategies for Design of Non Peptide CCK1R Agonist/Antagonist Ligands

Author(s): M. Teresa Garcia-Lopez, Rosario Gonzalez-Muniz, Mercedes Martin-Martinez and Rosario Herranz

Affiliation: Instituto de Quimica Medica (CSIC), Juan de la Cierva 3, E-28006 Madrid, Spain.


This review mainly covers last five year literature on CCK1R agonists and antagonists. These CCK1R ligands have been found following the two usual and complementary strategies for drug discovery: rational design based on structure activity relationships on the CCK-7 and CCK-4 peptide sequences of the endogenous ligands and random screening of diverse compounds, followed by hit optimization. The first group includes: chimeric bifunctional opioid/CCK peptides, designed as opioid agonists with balanced CCK1R/CCK2R antagonist activity for the treatment of neuropathic pain, antagonist and agonist dipeptoids, and 1,3-dioxoperhydropyrido[1,2-c]pyrimidine- and anthranilic acidbased antagonists. Among the ligands derived from random screening, a few new 1,4-benzodiazepine-, 1,5- benzodiazepine-, and five member ring heterocycle-based CCK1R ligands have been reported. Finally, taking into account the importance of receptor mapping studies for ligand optimization and future precise de novo receptor structurebased design of new selective and more effective ligands, the most significant conclusions of these studies have also been reviewed.

Keywords: CCK1R ligands, peptidomimetics, Dipeptoids, Anthranilic Acid, 1,5-benzodiazepine

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

Page: [1180 - 1194]
Pages: 15
DOI: 10.2174/156802607780960537